Zhou X, Radigue C, Allshouse AA, Gilsenan A. In Europe, how representative are overweight/obese subjects recruited via the internet? Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A326.
Javitt JC, Wolowacz SE, Roskell NS, Maciver F, Kelly S, Pleil AM, Zlateva GP. Cost-effectiveness of pegaptanib in age-related macular degeneration: the impact of differences between USA and UK health care systems. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Wolowacz SE, Roskell NS, Maciver F, Kelly S. Cost-utility analysis for pegaptanib in age-related macular degeneration in the UK: the impact of demographic and disease characteristics. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A370.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Lee WC, Joshi AV, Brown TM, Hadker N, Sumner M, Pashos CL. Physicians' preferences toward coagulation factor concentrates in the treatment of hemophilia patients with inhibitors: a discrete choice experiment. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; October 2006. [abstract] Value Health. 2006 Nov; 9(6):A251.
Meads DM, McKenna SP, Doward LC. Assessing the cross-cultural comparability of the Centre for Epidemiologic Studies Depression scale (CES-D). Poster presented at the 2006 ISPOR 9th Annual European Congress; October 2006. Copenhagen, Denmark. [abstract] Value Health. 2006 Nov; 9(6):A324.
Candrilli S, Mauskopf J. How much does a day in the hospital cost? Value Health. 2006 May 1;9(3):A56.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.
McCrink L, Beard SM, Le T. The relationship between health-related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A41.
McCrink L, Beard S, Le TK. The relationship between health related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain (DPNP). Value Health. 2006 May 1;9(3):A41.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Mladsi DM, Barrett AM. Winners and losers: patterns in economic evaluations of anti-epileptic drugs. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A83.